BioSpace News Archive

- Early clinical data of naked monoclonal antibodies support safety of targeting anti-Müllerian hormone receptor 2 (AMHR2), an oncology target of interest - - Antibody-drug conjugates (ADCs) targeting AMHR2 could provide clinical efficacy in gynecologic, colorectal and other forms of cancer -

Novamind Inc., a leading mental health company specialized in psychedelic medicine, is pleased to announce that it will open four new Cedar Psychiatry clinics, doubling its network to eight total locations.

In research to be shared during a plenary talk at the Society for Investigative Dermatology’s 2021 Virtual Meeting, data from investigators at the Tsai Lab at Moffitt Cancer Center, Sarin Lab at the Stanford University School of Medicine and NFlection Therapeutics demonstrate positive efficacy in preclinical models for the use of a topical gel — NFX-179 — to prevent cutaneous squamous cell carcinoma (cSCC).

Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will provide a corporate overview at the Bank of America Securities 2021 Virtual Healthcare Conference. The presentation will take place virtually on Tuesday, May 11, 2021, at 3:30 pm. ET.

Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)

FastLabs, a leading rapid laboratory and medical testing company, today announced that its new longitudinal case study was published on Authorea, the leading online collaborative research platform.

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, May 11, 2021, at 8:00 a.m. ET to review its first quarter 2021 financial results and provide an update on the company.

Palisade Bio, Inc., a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal complications, announced that it will host a key opinion leader webinar event on LB1148, the Company’s lead asset for indications associated with GI Surgery, on Thursday, May 13, 2021 at 1:00pm Eastern Time.

Talis Biomedical Corporation, a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, announced that it will release financial results for the first quarter after market close on Tuesday, May 11, 2021.

Biomedical startup company Phenomix Sciences (Phenomix) has signed an exclusive technology licensing agreement with Mayo Clinic for a novel blood test that accurately predicts obesity phenotypes. The multi-level “omics” MyPhenome™ test leverages technology developed at Mayo Clinic to analyze genomics, metabolomics and hormone levels.